12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Company News  |  Deals

Genmab, Kyowa Hakko Kirin deal

Genmab will use its DuoBody technology to create bispecific antibodies against an undisclosed target from Kyowa. Genmab said the deal includes an option to license rights to a DuoBody product....

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >